|
|
 | | | |
- close
- close
- close
- close
Benzinga
May 29
Comment
In a report published Wednesday, Piper Jaffray analyst Matt Miksic reiterated an Overweight rating on TranS1 (NASDAQ: TSON), but lowered the price target from $4.00 to $3.00.
In the report, Piper Jaffray noted, “We are updating our...
StreetInsider.com
Mar 4
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/TranS1%2C+Inc.+%28TSON%29+Reports+In-Line+Q4+EPS%3B+Guides+Q1+Revs/8150156.html for the full story.
StreetInsider.com
Jan 14
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/TranS1+Inc.+%28TSON%29+Pre-announces+Solid+Revenue/8004570.html for the full story.
Phil’s Stock World
Jan 1
Comment
Courtesy of Benzinga. TranS1 Inc. (Nasdaq: TSON), a medical device company focused on designing, developing and marketing products to treat degenerative conditions of the spine affecting the lower lumbar region, today announced that it had...
Benzinga
Dec 31
Comment
Barrington Research initiated coverage on TranS1 (NASDAQ: TSON) with an Outperform rating and a $4 price target.
Barrington Research said, "We estimate that the minimally invasive spinal fusion market is less than 30% of the total market and...
StreetInsider.com
Dec 27
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/TranS1+%28TSON%29+Reaches+Settlement+Over+Federal+Investigation%3B+Will+Pay+%246M/7971954.html for the full story.
StreetInsider.com
Oct 10
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/TranS1+%28TSON%29+Enters+AxiaLIF+Distribution+Agreement+in+China/7782996.html for the full story.
StreetInsider.com
Sep 17
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/TranS1+%28TSON%29+Tags+New+VP/7729888.html for the full story.
StreetInsider.com
Aug 9
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Guidance/TranS1%2C+Inc.+%28TSON%29+Misses+Q2+EPS+by+3c%3B+Guides+Q3+Revs/7647937.html for the full story.
Globe Newswire
Jul 3
Comment
WILMINGTON, N.C., July 3, 2012 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON), a pioneer in minimally invasive approaches to lumbar spine surgery, today announced it has received CE (Conformité Européenne) Mark approval in the European Union to
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS|
Error creating thumbnail: convert: unable to open image `/home/wikinvest/src_live_2/mediawiki/images/9/98/New_stock.png': No such file or directory @ blob.c/OpenBlob/2480. convert: unable to open file `/home/wikinvest/src_live_2/mediawiki/images/9/98/New_stock.png' @ png.c/ReadPNGImage/2889. convert: missing an image filename `/home/wikinvest/src_live_2/mediawiki/images/thumb/9/98/New_stock.png/35px-New_stock.png' @ convert.c/ConvertImageCommand/2800. |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
